Viking Therapeutics, Inc. (VKTX) Reaches $3.13 52-Week High; 5 Analysts Are Bullish Elementis plc (LON:ELM) Last Week

December 6, 2017 - By Kurt Siggers

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) hit a new 52-week high and has $3.35 target or 7.00% above today’s $3.13 share price. The 6 months bullish chart indicates low risk for the $89.20M company. The 1-year high was reported on Dec, 6 by Barchart.com. If the $3.35 price target is reached, the company will be worth $6.24 million more. The stock increased 14.23% or $0.39 during the last trading session, reaching $3.13. About 4.86 million shares traded or 594.53% up from the average. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 5.04% since December 6, 2016 and is uptrending. It has underperformed by 11.66% the S&P500.

Among 10 analysts covering Elementis PLC (LON:ELM), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Elementis PLC had 71 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Friday, December 18 by JP Morgan. Numis Securities maintained the stock with “Add” rating in Friday, October 27 report. Credit Suisse maintained the stock with “Outperform” rating in Friday, July 21 report. The firm has “Neutral” rating by Credit Suisse given on Thursday, October 8. The stock of Elementis plc (LON:ELM) has “Buy” rating given on Friday, October 30 by UBS. On Friday, October 30 the stock rating was maintained by N+1 Singer with “Corporate”. The firm earned “Hold” rating on Tuesday, November 1 by Numis Securities. The rating was maintained by Jefferies with “Hold” on Monday, February 13. Berenberg maintained the stock with “Buy” rating in Tuesday, December 22 report. JP Morgan maintained the stock with “Neutral” rating in Wednesday, August 3 report. See Elementis plc (LON:ELM) latest ratings:

27/10/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
30/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 285.00 New Target: GBX 285.00 Maintain
27/10/2017 Broker: Numis Securities Rating: Add Old Target: GBX 335.00 New Target: GBX 335.00 Maintain
26/09/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 285.00 New Target: GBX 285.00 Maintain
21/08/2017 Broker: UBS Rating: Buy New Target: GBX 340.00 Initiates Starts
04/08/2017 Broker: Numis Securities Rating: Add Old Target: GBX 331.00 New Target: GBX 335.00 Maintain
03/08/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 275.00 New Target: GBX 285.00 Reiteration
21/07/2017 Broker: Credit Suisse Rating: Outperform Maintain

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 11 analyst reports since April 7, 2016 according to SRatingsIntel. Maxim Group initiated Viking Therapeutics, Inc. (NASDAQ:VKTX) on Tuesday, May 24 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Thursday, August 10. The company was maintained on Wednesday, July 12 by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Monday, July 17. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by H.C. Wainwright on Friday, November 10. Roth Capital maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday, November 29 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Tuesday, November 21. Laidlaw maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) on Thursday, August 11 with “Buy” rating. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by Maxim Group on Tuesday, June 6. H.C. Wainwright initiated Viking Therapeutics, Inc. (NASDAQ:VKTX) on Thursday, April 7 with “Buy” rating.

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on March, 20. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.22 actual earnings per share reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.64% EPS growth.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $89.20 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.